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Aims: A complete clinical response after neoadjuvant chemotherapy (NACT) in breast cancer patients
hinders the localization of the residual lesion and the removal of a minimum amount of breast tissue. The
aim of the present work is to report our single-centre experience with intraoperative ultrasound-guided
(IOUS) excision performed by surgeons in these patients.
Patients and methods: From January 2008 to December 2012, IOUS excisions were performed on 58
patients with a previous intralesional ultrasound-detectable metallic marker and non-palpable breast
cancer after NACT. The specimen margins were estimated by ultrasonography and macroscopic patho-
logic examination. Successful lesion removal, specimen weight, and analysis of the results as regards
margins were evaluated, and the need for breast-conserving re-excision and mastectomy was
considered.
Results: After NACT the average ultrasound/mammography and MRI diameters were 11.7 mm (0e30) and
9.1 mm (0e40) respectively. In all cases, the residual lesion or tissue around the marker was removed.
The average weight of the specimens was 26.4 g (6e84), being lower in cases of complete response
according to ultrasound (p < 0.05). In 4 patients (6.8%), breast-conserving re-excision was carried out,
and in 3 patients (5.2%) a secondary mastectomy was performed, two of which had invasive lobular
carcinoma.
Conclusions: The emplacement of a readily echodetectable metal marker before NACT makes IOUS
excision feasible in an increasing number of complete clinical responses, with the excision of small
amounts of breast tissue and a high percentage of conservative breast surgery. This technique requires
surgeons to be trained, but has the advantage of a reduced use of other hospital services, better planning
of operating theatres, and less discomfort for patients, which means that it is attractive and indeed
recommendable.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Neoadjuvant chemotherapy (NACT) allows conservative surgery
to be performed on the breasts of women who are potential can-
didates for a mastectomy owing to the size of their tumours. The
complete and partial response rates for NACT are high according to
published works [1,2] indicating that a relatively high proportion of
these patients can beneﬁt from conservative surgery. However,
even though the clinical response is complete, surgery is alwaysby Elsevier Ltd. All rights reservedmandatory [3] since there may be residual cells in 70% of patients
[4]. Additionally, imaging studies only indicate the response of the
tumour to NACT but do not deﬁne the real surgical margins. Thus a
non-palpable tumour after NACT is a challenge for surgeons
because they must localize a non-palpable residual lesion intra-
operatively and, also, they must excise the minimum amount of
tissue to achieve tumour-free margins and be able to perform
conservative surgery with the best aesthetic result possible. In light
of these problems, it is crucial to mark the location of the tumour
before NACT [5] with metal clips or skin tattoos in case a complete
clinical response occurs later on. In these cases, after NACT and
prior to surgery it is necessary to localize the residual lesion or the
marking clip, but there is no standardized method for preoperative.
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removed. The wire-guided localization technique (WGL) is the
standard procedure but is a time-consuming procedure because it
requires the expertise of an experienced radiologist and it is un-
comfortable and usually stressful for the patient. Moreover it may
be associated with a high number of positive margins, increases in
local recurrences and a poor cosmetic result [6].
In view of the good results obtained with intraoperative ultra-
sound excision (IOUS) in suspicious lesions [7,8] and non-palpable
breast cancers [9,10], our aim here is to report our experience with
IOUS as an alternative toWGL in patients with breast cancer treated
previously with NACT in which the tumour or residual lesion was
non-palpable.
We analyse the surgical efﬁciency of IOUS excision using the
following parameters: the weight of the specimens excised, the
number of excisions with tumour-free margins and the proportion
of second operative procedures or mastectomies in patients who
were candidates for conservative surgery.
2. Material and methods
Using a prospective clinical database compiled at our Breast
Surgery Unit, between January 2008 and December 2012 we
identiﬁed patients diagnosed with a core breast biopsy as suffering
from invasive breast carcinomawho had been treated with NACT in
order to reduce the size of the tumour and perform conservative
surgery. The patients underwent diagnostic imaging studies with
ultrasound, mammography and MRI. After the NACT had been
completed, amultidisciplinary team decided on conservative breast
surgery after assessing the tumour response by physical explora-
tion and imaging studies.
The NACT protocol used at the discretion of the treating medical
oncologist was based on CAF (cyclophosphamide (600 mg/m2)/
epirubicin (90 mg/m2)/5-ﬂuorouracil (600 mg/m2) q 3 weekly  4
cycles, followed by docetaxel (100 mg/m2)  4 cycles or paclitaxel
(100 mg/m2) q weekly  8 weeks, depending on the patient’s age
and the characteristics of the tumour. If the tumour was also Her2-
positive, trastuzumab (2 mg/kg) q weekly was added throughout
the treatment period.
According to our protocol, before the patients were subjected to
NACT they received, under ultrasound control, a metal marker,
locating this as close to the tumour centre as possible. Although
IOUS has been applied gradually since 2007, in our study we only
analysed patients who had been ﬁtted with a non-ferromagnetic
clip. Such clips are readily localizable with ultrasound, owing to
their shape and size and they are also compatible with the MRI
exploration (MReye Breast Localization Coil, Cook Incorporated.
Bloomington, IN 47404, USA). We began to use these devices as of
January 2008. Later, the correct positioning of the clip was checked
by imaging studies, mammography and ultrasound.
A complete clinical response (cCR) was deﬁned by the absence
of clinical evidence on palpation at the time of surgery [4]. More-
over, the response to NACT was assessed by radiologists belonging
to the Multidisciplinary Breast Unit of our University Hospital, who
localized the marker and the size of the tumour (the greatest
diameter in mm) if it was measurable with mammography, ultra-
sound or MRI before the surgical intervention. A complete radio-
logical response (rCR) was deﬁned when there was no evidence of
lesions from the radiologic imaging studies, and tumour size was
deﬁned as the largest measurement obtained with any of the
techniques employed.
In these patients conservative surgery was indicated and IOUS
excision of the residual tumour was performed as an alternative to
other means used for preoperative localization. Cases in which a
WGL excision had beenmade and those inwhich the residual lesionor the marker were difﬁcult to detect by ultrasound were excluded
from the study. We also excluded all those cases who had under-
gone reducing oncoplastic techniques with or without contralateral
symmetrization, where the volume excised is much larger than in
classic lumpectomy.
Surgical resection with IOUS consisted of a residual tumor-
ectomy next to the marker or removal of breast tissue from around
the marker when no tumour was detected with pre and intra-
operative ultrasound. The idea was not to remove the pre-NACT
tumour volume but to eliminate the ultrasound-detectable resid-
ual tumour with negative margins in the pathological examination.
The ultrasound-guided excision technique has been described by us
previously [9]. The IOUS-excised specimen was oriented appro-
priately and marked three-dimensionally with sutures and the
margins were inked in. Then, the main tumour specimen was
weighed and additional cavity margins were included in these
measurements. Because the surgical specimen is not a sphere but
an ellipsoid, we believe that themost objective way of assessing the
excised breast tissue should be based on weight.
In all cases, using ultrasound and intraoperative gross study of
the specimenwe checked the removal of the marker in the cases of
complete ultrasound response and in the cases of partial response
we checked the removal of the marker and the tumour. In these
latter cases, the resection margins were assessed using ultrasound
and gross macroscopic pathologic examination jointly. Where the
presence of affected or close margins (<3 mm) was suspected, a re-
excision of the suspicious margin(s) was performed. No radiog-
raphy of the surgical specimens was carried out.
Complete pathological response in the breast (pCr) was deﬁned
when the surgical specimen did not contain invasive tumour cells.
When there were only clusters or dispersed cells remaining (>90%
loss), the case was considered as minimum residual disease (MRD).
When there was a measurable tumour, a 30e90% reduction in
tumour cells was considered a partial response (pPR). These three
classiﬁcations (pCR, MRD and pPR) coincide with scores 5, 4 and 3
of the tumour regression grade of Miller and Payne’s criteria,
respectively [11].
In cases of pPR or MRD, the margins of the specimen were
examined. The margin was considered histologically positive or
very close to the lesion if the carcinoma, invasive or “in situ”, was
localized at the margin or within an area <2 mm from the inked
border in the ﬁnal pathological examination [12]. In these cases, a
reoperation was performed, either re-excision of margins or a
mastectomy if a poor aesthetic result was foreseen. Margin status
was classiﬁed as negative if it was 2 mm.
Sentinel node biopsy was performed after NACT in those pa-
tients whose axilla was clinically negative by ultrasound or by ﬁne-
needle aspiration before and after NACT. In those with biopsy-
conﬁrmed axillary lymph node involvement before or after NACT,
full axillary lymph node dissection was performed. The combined
technique (blue dye plus isotope) was used for node staging by
subareolar intradermal injection.
Loco-regional recurrence (LRR) was deﬁned as recurrent disease
in the ipsilateral breast or in the axillary, supraclavicular, infracla-
vicular, or internal mammary lymph nodes. The time to LRR was
deﬁned as the time from initial tumour diagnosis to the time of the
last follow-up or development of LRR [13].
The study was observational and non-randomized, and was
based on prospective acquisition of data from a clinical database
compiled at our clinic. The clinico-pathological data, successful
lesion removal, specimen weight, and analysis of the results as
regards margins were evaluated, and the need for re-excision on
the same (synchronous) or on a different day (metachronous) was
considered. For the purposes of this study, the database holding
these patients was updated to include the clinical and radiological
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the axilla and on the breast. The outcome endpoints examined
were LRR and overall survival.
Statistical analyses. Descriptive data analysis was performed
and continuous variables between groups were tested using the t-
test for unpaired data. Data analysis was performed with the Sta-
tistical Package for the Social Sciences (SPSS statistical software,
Version 15.0; SPSS, Inc., Chicago, IL, USA).
3. Results
From January 2008 to December 2012, 122 breast cancer pa-
tients were treated at our breast surgical unit with neoadjuvant
chemotherapy for primarily operable breast carcinoma. In all cases,
prior to NACT a marker (MReye Breast Localization Coil) was placed
in the correct position in the lesion under ultrasound guidance, as
conﬁrmed bymammography. None of the radiologists encountered
difﬁculties in placing a marker and no complications occurred.
In 85 (69.7%) of these patients breast-conserving surgery was
indicated at the interdisciplinary meeting after NACT. In 27 of the
85 patients in which breast-conserving surgery was attempted, the
tumour was still palpable or an excision was performed via WGL or
using any of several different oncoplastic reduction methods. In the
remaining 58 (47.5%) patients a complete clinical response (cCR)
was considered to have occurred and a local excision was per-
formed with the use of the IOUS technique exclusively by surgeons
and these patients were included in the study.
The patient and tumour characteristics are summarized in
Table 1. The patients’mean agewas 48.57 9.6 years (31e77 years).
The radiological response was determined by mammography and/
or ultrasound in all cases and with MRI in 52 patients. According to
ultrasound/mammography and MRI the median tumour size pre-Table 1
Pre-NACT patients and tumour characteristics.
n ¼ 58 cases
Age in years (mean  sd) (range) 48.57  9.6 (31e77)
Clinical tumour size. Median (range) mm
By MRI (n ¼ 52) 33.1 (15e60)




T2 (3 cm) 18












Invasive ductal carcinoma 54 (93.1%)
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HER2þ 11NACT was 28.3 mm (11e53) and 33.1 mm respectively (15e60).
The majority of patients (79.3%) presented with T2 tumours.
After NACT, the diameter decreased to 11.7 mm (0e30) and
9.1 mm (0e40) in the imaging tests conducted with ultrasound/
mammography and MRI respectively. A complete radiological
response (rCR) was seen in 23 of 58 (39.7%) patients, while the rest
of the patients showed a partial or nearly complete radiological
response. 18 of the 58 patients (31%) achieved a pCR after NACT but
in the patients with an rCR, the cases of pCR increased to 52.2%
(Table 2).
In all cases, the metal marker (with or without residual lesion)
was removed, and successful excision of the metal marker and re-
sidual lesion was conﬁrmed by ultrasound with/without macro-
scopic intraoperative evaluation of the specimen, and with no need
for a mammogram. After intraoperative assessment of the margins
of the surgical specimen, compromisedmargins were deemed to be
present in 29 cases (50%) and the patient underwent intraoperative
re-excision of the margin(s) in question, with a total of 35 margins
(Table 3). In 9 cases residual invasive tumour was observed in re-
excision margins and 4 of these patients underwent reoperation
for inadequate microscopic margins. In another 5 cases (8.6%, 5/58),
the intraoperative ultrasound and macroscopic assessment and
appropriate directed re-excision achieved clear margins, circum-
venting a second procedure. Of the 29 cases with sufﬁcient intra-
operative ultrasound andmacroscopic margins, 3 were subjected to
a second operative procedure for themicroscopicmargins involved.
Overall, 7 patients underwent second interventions for unclear
margins; in 4 patients (6.8%) breast-conserving re-excision was
performed, and in 3 patients (5.2%) a mastectomy was performed.
In two of the latter patients the histologic diagnosis was invasive
lobular carcinoma (Table 4).
The average weight of the specimens studied here was 26.4 g
(6e84). On analysing the weight of the surgical specimens with
respect to the responses in the imaging studies and the pathologic
responses, we observed that the weights of the specimens were
signiﬁcantly lower (p < 0.05) in the complete responses observed
with ultrasound, there being no signiﬁcant differences in the MRI
and pathologic results (Table 5).
The median follow-up was 35 months (p25e75: 21e49
months); two patients (3.4%) developed LRR at 16 and 37 months.
One of these patients had LRR in the ipsilateral breast close to the
primary tumour site. Her initial IOUS specimen weighed 6 g and
had a pCR in its initial excision. The other patient developedTable 2
Treatment outcome.
Radiological response after chemotherapy
Partial response (rPR) 35
Complete response (rCR) 23 (39.5%)
Clinical tumour size. Median (range) mm
By MRI (n ¼ 52) 9.1 (0e40)
By US/mammogram (n ¼ 58) 11.7 (0e30)
Pathological response after systemic treatment
Partial response (pPR) 31 (18.7 6e55)
Minimal residual disease (MRD) 9
Complete response (pCR) 18 (31.0%)
Axillary lymphadenectomy 42
Sentinel node biopsy 16
Lymph node metastasis 13 (22.4%)
Weight of resected specimen (g), median (range) 26.4 (6e84)
Breast-conserving surgery 96.5%
Positive margins at the ﬁrst resection 7
Breast-conserving re-excisions 4 (6.8%)
Subsequent mastectomy 3 (5.2%)
Follow-up mediana (p25e75) (months) 35 (21e49)
LRR 1
LRR þ metastasis distant 1
Metastasis distant (death) 2 (1)
Table 3






Suspecteda 29 (50%) 9b 20
Negative 29 3c 26
Total 58 12 46
a Intraoperative re-excision margins.
b 5 patients with tumour in re-excised specimens (invasive or in situ) but with
clear margins, and 4 second therapeutic operations for non- clear margins (2 breast
conservative re-excisions and 2 mastectomies).
c 3 patients with second therapeutic operations (2 breast conservative re-
excisions and 1 mastectomie).
Table 5
Weight of the intraoperative specimen and its relationshipwith ultrasound, RMI and
pathologic complete/partial response.
(n patients) Specimen weight (g) (n patients)
Complete response Partial response
MRI (52) 28.2 (23) 23.6 (29)a
Ultrasound (58) 16.4 (11) 28.8 (47)b
Pathologic (58) 24.4 (27) 27.4 (31)c
Signiﬁcant p-values: ap ¼ 0.35, bp ¼ 0.04, cp ¼ 0.52.
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quadrant, with a weight of 26 g and pCR in its initial excision.
Another two patients also developed distant metastases and one of
them died (Table 2).
4. Discussion
It is unquestionable that surgical intervention in cases of breast
tumours after NACT is a challenge for breast surgeons, above all if
the tumour or the residual lesion is not palpable. The main aim of
administering NACT is to perform conservative surgery with
acceptable aesthetic results by removing the minimum amount of
breast tissue possible, although such an intervention must be suf-
ﬁcient to remove all the residual foci of echo-mammographically
evident disease and obtain negative histologic margins. Thus, pre-
dicting the size of the residual tumour is crucial for planning the
type of intervention to be performed and the volume of breast
tissue to be removed.
Although marking tumour margins prior to NACT has been
received well, the results are controversial [1,14,15] and the only
agreed method for orienting the surgeon when excising residual
tumours after NACT is to place a metal marker inside the tumour at
the start of NACT [5]; this serves as a guide for different methods of
post-NACT localization when the tumour is not palpable.
With a non-palpable tumour after NACT it is difﬁcult to locate
tumours or residual lesions and it is hard to determine the amount
of parenchyma around them to be excised. Accordingly, different
methods have been used for localization as alternatives to the
standard procedure by means of a wire guide [15e17]. Currently, as
far as we know, and after a Pubmed search (with terms non-
palpable breast cancer, intraoperative breast ultrasound, IOUS
breast, neoadjuvant chemotherapy, primary systemic therapy), the
present work is the only one to report on IOUS as a method for the
localization and excision of tumours or residual non-palpable le-
sions post-NACT.
At present, no reliable imaging methods are available for pre-
dicting a pCR, and MRI is the most accurate imaging technique toTable 4
Second therapeutic operations for nonclear margins. Ultrasound and pathological charac
# Patient Tumour diameter (mm)
Ultrasound Pre-NACT Ultrasound post-NACT Pathologic
1 40 15 10
2 23 13 10
3 26 18 22
4 30 RC 55
5 15 7 13
6 34 21 50
7 30 12 12assess tumour response after NACT [18], although with a negative
predictive value close to 65%. The ultrasound study, althoughwith a
lower negative predictive value, is still a valid option for the
assessment of tumour size and the surgical strategy to be used [19e
23]. IOUS is the only method that excises the residual lesion
together with the ultrasound-detectable clip by means of images
taken intraoperatively, avoiding excess removal of breast tissue,
which is incompatible with the aesthetic aspect of conservative
surgery. IOUS excision achieves this aim since the surgeon is better
able to plan the surgical technique to be used and the volume to be
excised because with images acquired in real time it is possible to
localize the residual tumour and the marker in their exact spatial
position during the operation. It is important that the marker be
readily echodetectable and compatible with MRI because the
objective of IOUS is to localize it and excise it together with the
residual lesion close to it. This is different from other techniques
(ROLL and WGL), where the marker is used to “highlight” the
localization of the lesion by injecting a radiotracer or by placing a
metal guide wire.
The most determinant factor with respect to affected margins
and cosmetic outcome [24] is the amount of breast tissue removed
around the residual lesion. The greater the volume removed, the
fewer the affected margins, but the poorer the aesthetic results.
According to the work of Loibl et al. [25], re-excisions were more
frequent after segmentectomy than after quadrantectomy (24.1%
vs.19.3%). In non-palpable lesions after neoadjuvant chemotherapy,
Van Riet et al. [16], using radioactive 125 Iodine seed, and Donker
et al. [26], comparing radioactive seed localization versus ROLL,
reported a mean specimen weight of 39 and 48e53 g respectively.
In our patients, with IOUS excision, mean specimen weight was
considerably lower (26.4 g). We believe that this lower specimen
weight in IOUS would be due to the fact that the surgeon, with
information about the preoperative ultrasound images post-NACT,
mainly performed an excision of the residual lesion and/or the
marker with adequate margins. In support of this hypothesis is the
lower ultrasound specimen weight (p < 0.05) when it was only
necessary to excise the marker because no ultrasound residual
tumour lesion was detected (Table 5).
In our patients conservative surgery was performed in 94.8% of
cases, similar or higher to what has been reported in other series:
96.3% [16], 94% [26], and 82.7% [25]. In the meta-analysisteristics and deﬁnitive surgery.








M. Ramos et al. / International Journal of Surgery 12 (2014) 572e577576
ORIGINAL RESEARCHperformed by Loibl et al. [25] on patients with a complete clinical
response, the percentage of re-excisions performed because of
affected margins was 19.6%. Accordingly in our serie, in 6.6% pa-
tients it was necessary to carry out a second breast-conserving re-
excision and in 8.6% a second procedure was avoided with an
appropriate re-excision directed by ultrasound and macroscopic
intraoperative evaluation, obtaining clear margins. Although they
excised twice the breast volume, Donker et al. [26] reported 13% of
affected margins for the two localization methods employed
(radioactive seed localization versus ROLL), but those authors only
performed 7 and 8% of re-excisions. Van Riet et al. [16], using a
radioactive seed, observed similar numbers of affected margins
(6.4%), but differed from our series in that the tumours were
grouped as palpable and non-palpable and in that those authors
removed a greater weight of breast tissue. Espinosa-Bravo et al.
[15], analysing two localization techniques in patients in which
conservative surgery had been performed, found 5.9% and 3.2% of
affected margins, but we believe that these ﬁndings cannot be
compared with our own because those authors analysed patients
with palpable and non-palpable residual tumours and, also,
because of the greater volume of breast tissue removed. On
comparing IOUS excision in non-palpable breast cancers without
NACT, the percentage of affected margins was lower (4%) [9]. This
could be because in tumours not treated with NACT a more precise
assessment of the margins can be gained with ultrasound [27] and
intraoperative macroscopic studies [9].
Upon analysing the seven re-excisions according to histologic
types (Table 4), 5 were found to be ductal and 2 were lobular car-
cinomas, representing 11% and 66% of the ductal and lobular car-
cinomas treated with NACT respectively. These data are consistent
with those reported in the GEPARDUO trial [25], in which re-
excisions and mastectomies were seen to be more frequent in
lobular carcinomas and conservative breast surgery was less
frequent in patients with a partial clinical response. Like other
authors [28] we believe that this would be due to the smaller and
non-concentric pathological pattern response and the difﬁculty
involved in determining the post-NACT extent of lobular carci-
nomas by imaging techniques.
Just as in non-palpable cancers [9], it should be taken into ac-
count that this technique does not interfere in sentinel node biopsy,
because in our cases we injected dye and radiotracer under the
areola. Neither is it necessary to use the radiology service preop-
eratively, with less discomfort for the patient, nor to take a radio-
graph of the operation specimen, since the marker and the residual
lesion, if indeed present, are checked with IOUS. Accordingly, IOUS
excision is less complex than other methods, which saves time and
money [29] owing to a reduction in the use of radiology and nuclear
medicine and decreases the number of second interventions.
One of the limitations of this study is that the follow-up period
for assessing the LRR was very short, since according to most au-
thors [13,30] the follow-up period is longer and the mean interval
between local relapses in other studies is longer than our follow-up
period. Accordingly, we should have used a longer follow-up to
detect possible cases of LRR. Although the amount of breast tissue
to be removed is not deﬁned, if LRR were to remain at acceptable
levels after a longer follow-up period it could be proposed that with
small excision volumes it would be possible to achieve excellent
local control.
5. Conclusions
Although the technique takes surgeons some time to master,
with IOUS is it possible to perform the excision of a small amount of
breast tissue in non-palpable tumour after NACT, the ﬁrst factor to
be considered for conservative surgery with good aesthetic results.Moreover, with this technique it is also possible to achieve a low
number of breast-conserving re-excisions due to affected margins,
which would afford cost-savings and good local control. We believe
that this is because with IOUS it is possible to focus the residual
lesion or marker in the surgical specimen, allowing a smaller vol-
ume of tissue to be excised and greater possibilities of free margins.
These advantages, together with a reduced use of other hospital
services, better planning of operating theatre schedules and the
reduced discomfort for patients make IOUS excision an attractive
and recommendable practice as an alternative to other excision
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